Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Correspondence
  • Published:

Response to “Graft-versus-myeloma: are durable responses a clinical reality following donor lymphocyte infusion?” by Peggs et al

Leukemia volume 18, pages 1542–1543 (2004)Cite this article

TO THE EDITOR

The correspondence by Karl Peggs and Stephen Mackinnon1 confirms our previously published data showing that remission can be achieved in myeloma patients who have relapsed, persistent or progressive disease after RIC allografting with relatively low T-cell doses.2 They also confirm the close association of response with development of GvHD as well as the higher incidence of GvHD in recipients of unrelated grafts even at such low donor lymphocyte infusion (DLI) doses. These results are comparable to those observed after full intensity allografting. Our data with low-dose DLI did show a lower risk of GvHD compared to other studies with higher doses.2

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. Peggs K, Mackinnon S . Graft-versus-myeloma: are durable responses a clinical reality following donor lymphocyte infusions? Leukemia 2004 July 8 [Epub ahead of print].

  2. Ayuk F, Shimoni A, Nagler A, Schwerdtfeger R, Kiehl M, Sayer HG et al. Efficacy and toxicity of low-dose escalating donor lymphocyte infusion given after reduced intensity conditioning allograft for multiple myeloma. Leukemia 2004; 18: 659–662.

    Article  CAS  Google Scholar 

  3. Lokhorst HM, Wu K, Verdonck LF, Laterveer LL, Van De Donk NW, Oers MH et al. The occurrence of graft versus host disease is the major predictive factor for response to donor lymphocyte infusions in multiple myeloma. Blood 2004; 103: 4362–4364.

    Article  CAS  Google Scholar 

  4. Corradini P, Cavo M, Lokhorst H, Martinelli G, Terragna C, Majolino I et al. Chronic leukemia working party of the European Group for Blood and Marrow Transplantation (EBMT). Molecular remission after myeloablative allogeneic stem cell transplantation predicts a better relapse-free survival in patients with multiple myeloma. Blood 2003; 102: 1927–1929.

    Article  CAS  Google Scholar 

  5. Zargrivnaja M, Fehse B, Zander A, Kröger N . Induction of molecular remission by donor lymphocyte infusions in patients with multiple myeloma and residual disease after dose-reduced conditioning and allogeneic stem cell transplantation. Bone Marrow Transplant 2004; 33 (Suppl 1): R1161.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. BMT Unit, University Hospital Hamburg, Hamburg, Germany

    F A Ayuk, A R Zander & N Kröger

Authors
  1. F A Ayuk
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. A R Zander
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. N Kröger
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to F A Ayuk.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Ayuk, F., Zander, A. & Kröger, N. Response to “Graft-versus-myeloma: are durable responses a clinical reality following donor lymphocyte infusion?” by Peggs et al. Leukemia 18, 1542–1543 (2004). https://doi.org/10.1038/sj.leu.2403433

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.leu.2403433

Search

Advanced search

Quick links